GlassScriptPhysician profile
Brenen Swofford
NPI 1447614110
$1,423.60
in general payments reported to CMS, 2019-2025
20 companies · $986 in 2025
The $986 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.35 · 2023: $90.17 · 2024: $325 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327 · Education: $74.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.22 |
| Education | $74.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $357.98 | 2024-2025 | |
| Janssen Biotech, INC. | $148.93 | 2024-2025 | Tecvayli, Erleada, Talvey |
| Celgene Corporation | $120.44 | 2022-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $116.43 | 2025 | Zejula, Jemperli, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $87.24 | 2023-2025 | Opdualag, Sprycel, Opdivo |
| Pfizer INC. | $73.51 | 2025 | |
| Merck Sharp & Dohme LLC | $66.61 | 2025 | Keytruda, Lynparza |
| Array Biopharma INC | $64.08 | 2025 | Xalkori, Lorbrena, Braftovi |
| Eisai INC. | $61.97 | 2025 | |
| Acrotech Biopharma INC. | $48.76 | 2024-2025 | Beleodaq |
| Abbvie INC. | $44.26 | 2025 | |
| Genzyme Corporation | $41.28 | 2023 | |
| Dendreon Pharmaceuticals LLC | $34.63 | 2025 | Provenge |
| Daiichi Sankyo INC. | $28.19 | 2025 | Enhertu |
| Lilly USA, LLC | $26.50 | 2025 | Verzenio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $25.95 | 2024 | Enhertu |
| Astellas Pharma US INC | $24.92 | 2025 | Cresemba |
| Azurity Pharmaceuticals, INC. | $21.67 | 2025 | Danziten |
| Fennec Pharmaceuticals, INC. | $16.49 | 2024 | Pedmark |
| Morphosys, US INC. | $13.76 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenen Swofford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.